Studies for colorectal cancer patients whose ctDNA test is positive after surgery and chemotherapy. Recruitment status, phase, and sites are pulled from ClinicalTrials.gov so they stay current.
Showing 17 trials
This is a Phase II trial to study whether the combination of botensilimab and balstilimab, followed by balstilimab alone, is an effective treatment for CRC patients with MRD after standard treatment with surgery and chemotherapy or total neoadjuvant therapy.
This is a study to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment.
This is a study to assess the effects of the drugs Regorafenib and Lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy.
This is a study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.
This is a study to assess adverse events and change in disease activity in adult participants receiving intravenously infused Telisotuzumab Adizutecan alone or with standard of care in participants with post adjuvant circulating tumor DNA positive colorectal cancer and no radiographic evidence of di
This is a Phase 2 trial studying anti-CSF1R antibody in patients with ctDNA positive colorectal cancer minimal residual disease after completion of standard therapies.
This is an observational study, monitoring participants while receiving standard-of-care biomarker-directed therapy with the goal to learn about the effects of these therapies on ctDNA in participants with minimal residual colorectal cancer.
This is a Phase Ib, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
This is a Phase II trial studying atezolizumab and bevacizumab in ctDNA positive colorectal cancer patients with no evidence of cancer on imaging after completing standard therapies.
To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
This is a Phase II/III trial across North America cooperative groups to study what kind of chemotherapy to recommend to low risk, Stage III colon cancer (T1-3, N1) patients based on the presence or absence of ctDNA after surgery for colon cancer.
ctDNA positive patients randomized to FOLFIRI (12 cycles) or surveillance. If MSI-H, receive nivolumab (12 cycles). If BRAF mutation is present, receive encorafenib, binimetinib, and cetuximab (12 cycles).
This is an upcoming trial to study the effect of a botensilimab and balstilimab regimen in CRC patients with MRD after completing definitive standard-of-care therapy.
This is a Phase II trial to study control of MRD with a combination of Fruquitinib (VEGFR inhibitor) and Tislelizumab (PD-1 inhibitor) in CRC patients after adjuvant chemotherapy.
This is a study designed to evaluate varying doses of TROP2-CAR-NK cells combined with cetuximab and their ability to clear ctDNA in patients with minimal residual colorectal cancer.
This is a single arm Phase II cohort of RO7198457 in patients with circulating tumor DNA (ctDNA) positive surgically resected Stage IV CRC after standard of care adjuvant therapy. The study will test whether the vaccine can reduce recurrence of the cancer.
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal or colon. The study will test whether the vaccine can reduce recurrence of the c
Status and site data from ClinicalTrials.gov, last refreshed September 5, 2026. Eligibility summaries are written by our contributors; confirm details with the study team before making decisions. Know of a trial we're missing? Let us know.
One email when something new is posted: a new clinical trial, meeting highlights, or educational material. No spam, unsubscribe any time.